Xenotransplantation:
Regulatory and Ethical Considerations with Best Practices for Sponsors and IRBs

Xenotransplantation, the use of animal organs in human recipients offers a possible solution to organ shortages but faces notable scientific, ethical, and regulatory hurdles. Major issues include immune rejection, zoonotic infection risks, long-term monitoring, participant vulnerability, animal welfare concerns, and equitable access. Effective oversight, transparent consent, multidisciplinary collaboration, and ongoing research are essential for success of clinical trials. This article reviews major ethical and regulatory considerations and outlines recommended practices for sponsors and Institutional Review Boards (IRBs) engaged in xenotransplantation clinical trials.

The global shortage of human donor organs remains one of the most persistent and life-limiting challenges in modern medicine. Thousands of patients die each year while waiting for a suitable organ, highlighting the need for innovative solutions. In the United States, more than 103,000 people are on the transplant waiting list, and 13 die daily waiting for organs. About 86% need a kidney, 9% need a liver, and 3% need a heart.[1] Xenotransplantation, the transplantation of organs, tissues, or cells from non-human animals into humans has emerged as a promising frontier, potentially offering a virtually limitless supply of donor organs. With recent advances in genetic engineering and immunology, the transplantation of genetically modified pig organs into human recipients is transitioning from experimental feasibility to clinical reality. However, this unprecedented progress brings equally significant regulatory, ethical, and public health challenges. A deeper look at the key ethical and regulatory issues will provide recommended practices for sponsors and Institutional Review Boards (IRBs) involved in xenotransplantation clinical trials.

Scientific Advances and Remaining Hurdles

The scientific landscape of xenotransplantation has evolved rapidly, driven by the application of gene-editing technologies such as CRISPR to create genetically modified pigs whose organs are less likely to be rejected by the human immune system.[2,3,4] Notable milestones include the successful transplantation of pig hearts and kidneys into human recipients under expanded access protocols, which have demonstrated that animal organs can function in human bodies for limited durations.[5] These first-in-human cases are invaluable for understanding immune responses and refining surgical techniques.

Despite these advances, several formidable hurdles remain. Immune rejection, both immediate and delayed, continues to pose a significant challenge, necessitating the use of powerful immunosuppressive therapies with their own risks. The possibility of zoonotic infections, where diseases are transmitted from animals to humans, is a persistent concern, especially with the potential emergence of novel pathogens.6 Vigilant screening, lifetime monitoring of recipients, and surveillance of close contacts are essential strategies to mitigate the risk of zoonosis. However, the possibility of unforeseen infectious outbreaks remains a public health consideration.

The long-term durability and functionality of xenografts are not yet fully understood, and standardising protocols for the production and use of genetically engineered animal organs remains a work in progress. Technical challenges in organ procurement, preservation, and transplantation further complicate the path to routine clinical use.

Ethical Considerations

The ethical landscape of xenotransplantation is as complex as its scientific one. Key ethical considerations include the protection of participant autonomy through robust informed consent, the welfare and rights of animal donors, the fair allocation of resources, and the broader social and public health implications of introducing animal organs into human recipients.[7,8,9,10]

a. Informed Consent and Participant Autonomy

Given the experimental nature of xenotransplantation, informed consent is of paramount importance. Participants must be provided with clear, comprehensible information about the procedure's risks, including immune rejection, zoonotic disease transmission, and potential long-term complications alongside alternative treatment options (such as traditional transplantation or medical management). The consent process must also address the implications of lifelong monitoring and potential impacts on quality of life. Particular attention is needed for participants with limited options, who may be especially vulnerable to coercion or undue influence.

b. Animal Welfare and Rights

The use of animals as organ donors raises profound ethical questions about animal welfare and rights. Donor animals, typically pigs, must be bred and maintained in pathogen-free, humane environments, with regulatory oversight ensuring their well-being and minimising suffering. Ethical guidelines require that animal use is justified only when there are no viable alternatives and that the benefits to human health are substantial and proportionate. The potential for genetic modification to enhance organ compatibility introduces further ethical complexity, demanding transparency, and public engagement in the development of standards.

c. Equity, Access, and Public Perception

Equitable access to xenotransplantation is essential to prevent widening disparities in healthcare. The initial high costs and technical complexity of these procedures may limit access to affluent populations unless deliberate efforts are made to ensure fairness. Additionally, public perception shaped by concerns about "species boundaries," religious beliefs, and fears of new infectious diseases can influence the acceptance and success of xenotransplantation programs.

d. Societal and Psychological Impacts

Recipients may experience psychological effects related to identity, stigma, or the burden of lifelong monitoring. The risk to close contacts and the broader public from zoonotic diseases also raises public health and societal concerns.

e. Human-Animal Chimeras

Xenotransplantation complicates human-animal distinctions, raising ethical debates about species boundaries and moral obligations.

Regulatory and Ethical Oversight: Role of IRBs

Xenotransplantation clinical trials are subject to rigorous regulatory and ethical review to ensure participant safety and scientific integrity. Institutional Review Boards (IRBs) play a central role in this process, guided by the regulatory frameworks outlined in 45 CFR §46.111 and 21 CFR §56.111.[11,12] These regulations mandate systematic risk minimisation, equitable participant selection, comprehensive informed consent, ongoing safety monitoring, and additional protections for vulnerable populations.

Best Practices for Sponsors and Investigators

Sponsors are instrumental in upholding the scientific rigor, safety, and ethical standards of xenotransplantation clinical trials. They must maintain source animals in pathogen-free, closely monitored herds to minimise zoonotic risks and provide robust preclinical



IRB Criteria for Approval	IRB Review Considerations
111.a.1 Risks to subjects are minimised by sound research design and using procedures already being performed on the subjects for diagnostic or treatment purposes. 111.a.2 Risks are reasonable in relation to anticipated benefits and the importance of the knowledge.	• Weigh benefits to participants against risks including organ rejection, zoonotic infection, and public health implications. • Robust justification for participant inclusion. • Use of immunosuppressive and supportive therapies. • Strategies for early detection of immune rejection, infections to ensure safety and efficacy. • Ensure protocols include lifetime monitoring of recipients, close contacts, and healthcare workers for infectious diseases • Ensure multispecialty experts in infectious diseases, immunology, animal husbandry, and bioethics.
111.a.3 Selection of subjects is equitable.	• Ensure fair and transparent participant selection to uphold justice and prevent exploitation. • Ensure criteria that prioritise individuals with life-threatening conditions and limited treatment alternatives. • Avoid excluding qualified candidates based on socioeconomic status or lack of access to waitlists. • Assess the risk of coercion or undue influence in the selection process.
111.a.4 Informed Consent	• Ensure robust process due to experimental nature, recipient vulnerability, societal risks • Ensure participants have comprehensive understanding of risks and benefits, novelty, immune rejection, zoonotic infection, long-term monitoring, psychological impacts, future healthcare implications. • Look for alternative treatments; protocols for managing graft failure and returning to previous therapies. • Close contacts information about risks and monitoring, especially for infectious disease surveillance.
111.a.6 Adequate provision for monitoring data collected to ensure the safety of subjects.	• Lifetime surveillance for infectious disease detection, graft function; protocols for continuous monitoring, registries, tissue/sample banking, quarantine plans, defined responsibilities and funding for monitoring/care. • Collaborate with IBC (Institutional Biosafety Committee), IACUCs (Institutional Animal Care and Use Committees), DSMBs, and regulatory agencies to ensure ongoing compliance and oversight.
111.b Additional protection for vulnerable subjects.	• Consider research purpose, setting, and special attention for vulnerable groups to prevent coercion or undue influence.

data, often from non-human primate studies, that demonstrate safety and efficacy. Participant selection should be equitable, focusing on individuals with life-threatening conditions lacking alternative treatments and ensuring diverse representation. Lifelong monitoring of recipients and their close contacts, comprehensive registries and sample banking, and independent data safety monitoring are essential for ongoing research and public health. Multidisciplinary teams with experts in infectious disease, immunology, surgery, animal husbandry, and bioethics should oversee trials, utilising accredited laboratories for pathogen screening. Sponsors must collaborate closely with regulatory authorities, including the FDA, IRBs, and IBCs, to ensure timely reporting of adverse events and protocol amendments. Engaging with participants, families, advocacy groups, and the broader public through transparent communication and educational initiatives is vital for fostering trust and acceptance.[13] Sponsors should also clearly define responsibilities for the costs of long-term care, both during and after the trial, to support accessibility and proper oversight.

Conclusion

Xenotransplantation stands at a transformative juncture in medicine, offering hope to thousands of patients awaiting life-saving organ transplants. Its potential to alleviate organ shortages is matched by significant scientific, ethical, and regulatory challenges that demand careful attention. Responsible advancement requires rigorous scientific evaluation, robust ethical safeguards, and comprehensive regulatory oversight. Key priorities include the protection of participant autonomy through informed consent, the humane treatment of animal donors, equitable access to care, and ongoing research to refine clinical protocols and risk mitigation strategies.

Continued dialogue among researchers, regulators, ethicists, and society at large will be essential for navigating the evolving landscape of xenotransplantation. Following best practices in protocol design, risk assessment, animal welfare, and stakeholder engagement will help to ensure xenotransplantation is safe, ethical, and equitable for all.

REFERENCES

1. https://www.organdonor.gov/learn/organ-donation-statistics
2. Hai T, Teng F, Guo R, Li W, Zhou Q. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res (2014) 24:372–75. doi: 10.1038/cr.2014.11
3. Cowan PJ, Hawthorne WJ, Nottle MB. Xenogeneic transplantation and tolerance in the era of CRISPR-Cas9. Curr Opin Organ Transplant (2019) 24:5–11. doi: 10.1097/MOT.0000000000000589
4. Bobier C, Hurst DJ, Rodger D. Xenotransplantation under the Food and Drug Administration's Expanded Access pathway. Am J Transplant. 2024 Oct;24(10):1911-1912. doi: 10.1016/j.ajt.2024.05.015. Epub 2024 May 22. PMID: 38782186.
5. George AJ. Ethics, virtues and xenotransplantation. Perfusion. 2024 Mar;39(2):334-343. doi: 10.1177/02676591221140767. Epub 2022 Nov 16. PMID: 36382884; PMCID: PMC10900854.
6. George AJ. Ethics, virtues and xenotransplantation. Perfusion. 2024 Mar;39(2):334-343. doi: 10.1177/02676591221140767. Epub 2022 Nov 16. PMID: 36382884; PMCID: PMC10900854.
7. Sade RM, Mukherjee R. Ethical issues in xenotransplantation: The first pig-to-human heart transplant. Ann Thorac Surg 2022; 113: 712–714.
8. Entwistle JW, Sade RM, Drake DH. Clinical xenotransplantation seems close: Ethical issues persist. Artif Organs 2022; 46: 987–994.
9. Johnson LSM. Existing ethical tensions in xenotransplantation. Camb Q Healthc Ethics 2022; 31: 355–367.
10. Cengiz N, Wareham CS. Ethical considerations in xenotransplantation: a review. Curr Opin Organ Transpl 2020; 25: 483–488.
11. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/subpart-A/section-46.111
12. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-56/subpart-C/section-56.111
13. Hawthorne WJ. Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation. Front Immunol. 2024 Feb 7;15:1355609. doi: 10.3389/fimmu.2024.1355609. PMID: 38384454; PMCID: PMC10880189.

Sharad Adekar

Sharad Adekar, MD, PhD, CIP, is a Senior Medical Chair at WCG. He is a physician scientist with clinical experience in family practice and pediatrics and research experience in immunology, oncology, cardiovascular diseases, infectious diseases, and neurology. Dr. Adekar has experience in human antibodies in terms of discovery, lead optimisation, and preclinical development of monoclonal antibody therapeutics.

Ronald Quinton

Ronald Quinton, MD, is the medical director of the Goldring Center for Culinary Medicine at Tulane University School of Medicine. He is a certified culinary medicine specialist and is board-certified in thoracic surgery. Dr. Quinton also serves as an adjunct professor at the Tulane School of Medicine. He graduated from the U.S. Air Force Academy with a degree in life science, then earned a medical degree from the Tulane School of Medicine.